Dexcom Gets FDA Warning Letter

DexCom Stock Drops as Diabetes Devices Maker Gets FDA Warning Letter
Key Takeaways DexCom received a warning letter from the Food and Drug Administration following inspections of two of its plants.The maker of glucose monitoring devices said investigations of its San Diego,
Dexcom receives FDA warning letter for two U.S. manufacturing facilities
Medical device maker Dexcom said it has received a warning letter from the U.S. Food and Drug Administration following inspections of its two key manufacturing facilities, sending its shares down nearly 7% after the bell.
Dexcom receives warning letter based on FDA inspections of 2 plants
The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek clearance for new products.
Dexcom receives FDA warning letter over CGM manufacturing issues
Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous glucose monitor maker’s facilities last year. | Dexcom has received a warning letter from the FDA,
DexCom Gets FDA Warning Letter After Inspections of Facilities
DexCom received a warning letter from the Food and Drug Administration following inspections of its San Diego and Mesa, Ariz. facilities and is working on a written response.
DexCom receives warning letter from FDA, sees no impact to FY25 guidance
In a regulatory filing, DexCom (DXCM) disclosed that on March 4, the company received a warning letter from the U.S. FDA following inspections
Dexcom receives FDA warning letter
Dexcom (Nadsaq:DXCM) announced today that it received a warning letter from the FDA following inspections of two company facilities.
Wells sees no material impact from DexCom warning letter
Wells Fargo analyst Larry Biegelsen keeps an Overweight rating on DexCom (DXCM) with a $98 price target after the company disclosed that a warning
DexCom sees no material impact from warning letter on sales outlook
DexCom (DXCM) does not expect a material impact from the FDA’s warning letter to its manufacturing capacity or its fiscal year 2025 guidance
DexCom falls after warning letter from FDA related to quality concerns
DexCom said that on Tuesday it received a warning letter from the U.S. FDA following inspections at its facilities in San Diego, California, and Mesa, Arizona related to concerns about manufacturing processes and quality management systems.
Healthy Returns: Wegovy is linked to an increased risk of hair loss, study suggests
Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...
DexCom (NasdaqGS:DXCM) Shares Dip 1% Despite 7% Sales Growth
DexCom (NasdaqGS:DXCM) recently received a warning letter from the FDA, which pointed out issues in manufacturing processes and quality management. While these regulatory developments did not impact ...
Devdiscourse3d
Health Headlines: Major Drug Halts, Egg Price Probe, and More
The latest health news includes Johnson & Johnson halting testing on a depression drug, USDA eliminating food safety advisory ...